All In Biotech

Drug Trial Radar · NCT07016750

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Jun 20, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Krystal Biotech, Inc.Industry
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Conditions

  • Dystrophic Epidermolysis Bullosa
  • DEB - Dystrophic Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • Dominant Dystrophic Epidermolysis Bullosa

Interventions

  • KB803Biological

    Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein

  • PlaceboDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of KB803.Time frame: 24 weeks
  2. To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms.Time frame: 24 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Mission Dermatology Center

    Rancho Santa Margarita, California · Recruiting

  • Skin Research Institute

    Coral Gables, Florida · Recruiting

  • UMass Memorial Medical Center

    Worcester, Massachusetts · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.